Obatoclax Mesylate (GX15-070)

Catalog No.S1057

Molecular Weight(MW): 413.49

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Cited by 26 Publications

Nat Chem Biol, 2015, 10.1038/nchembio.1986

PubMed: 26656090

Cancer Res, 2012, 72(12):3069-79

PubMed: 22525702

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370

ACS Appl Mater Interfaces, 2016, 8(21):13218-31

PubMed: 27160664

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751

Cancer Lett, 2015, 10.1016/j.canlet.2015.05.008

PubMed: 25979228

Cancer Lett, 2014, 348(1-2):20-8

PubMed: 24534203

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668

Cell Death Dis, 2013, 4:e742

PubMed: 23887633

Cell Death Dis, 2012, 3:e351

PubMed: 22825469

Cell Death Dis, 2012, 3:e299

PubMed: 22513873

Mol Oncol, 2015, 9(2):409-21

PubMed:
Oral Oncol, 2014, 50(2):120-7

PubMed: 24216166

Antimicrob Agents Chemother, 2014, 58(7):3689-96

PubMed: 24752266

Biochem Pharmacol, 2014, 92(1):55-61

PubMed: 25107702

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574

Exp Cell Res, 2014, 322(1):217-25

PubMed: 24355809

Open Biol, 2015, 5(3)

PubMed: 25761368

Life Sci, 2014, 10.1016/j.lfs.2014.07.006

PubMed: 25066930

J Cell Biochem, 2014, 115(9):1624-35

PubMed: 24788582

PLoS One, 2014, 9(9):e106571

PubMed: 25192188

PLoS One, 2013, 8(2):e55982

PubMed: 23418490

Anticancer Drugs, 2015, 26(3):331-42

PubMed: 25521557

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608
Erasmus University Rotterdam, 2014, 978-94-6259-077-9

PubMed: http://repub.eur.nl/pub/50827/

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed:

9 Customer Reviews

In vivo antitumor efﬁcacies of AZD2281 and GX15-070 alone or in combination in a BxPC-3 xenograft model. Tumor specimens were fixed in 10% formalin, embedded in paraffin, and cut into 4 lm-thick slides for H&E, PCNA, and CD34 staining.

Cancer Lett 2014 348, 20-8. Obatoclax Mesylate (GX15-070) purchased from Selleck.

Gx15-070 induces autophagy and necroptosis in TET cells. Time-course electron microscopic morphology of T1682 cells treated with Gx15-070 at the indicated concentrations. After 1-h treatment, lamellar bodies (yellow arrow) consistent with early signs of autophagy and mitochondrial structural changes with loss of cristae (orange arrow) were evident. After 6-h treatment, early signs of necroptosis with intact nuclear envelope (top panel), and mitochondrial swelling with loss of mitochondrial matrix and cytoplasm vacuolization were observed (bottom panel). After 48-h treatment, late stages of necroptotic cell death (yellow arrow) and advanced stages of autophagy (orange arrow) were evident. The bottom panel depicts advanced stage of autophagic cell death with cytoplasmic vacuolization and lamellar bound structures consistent with autophagosomes.

Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.
ffect of Gx15-070 of mTOR pathway and on AMPKα. Effect of 6h Gx15-070 treatment on T1682 cells compared with untreated cells and cells starved for 6 h. The treatment induced a progressive reduction of p-AKT (Ser473 and Thr308) and p-RPS6 with the exception of 500 nM concentration. Progressive increase of LC3B-II and AMPKα phosphorylation was observed in Gx15-070 concentration-dependent manner.

Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.

Upregulation of A1 is crucial for resistance to ABT-737. The role of different anti-apoptotic Bcl-2 factors in determining resistance to ABT-737 was investigated, comparing the pro-apoptotic effect of ABT-737, antimycin A and obatoclax on activated (filled circles) and non-activated (open circles) BM3.3 CD8 T cells. T-cell activation induced resistance to ABT-737 and to antimycin A, but not to obatoclax, demonstrating a crucial role of A1 in this phenomenon. Percentage of cells treated with DMSO-containing vehicle is given. Half maximal inhibitory concentration (IC50) and 95% confidence interval (95% CI) are reported in the table.

Cell Death Dis 2012 3, e299. Obatoclax Mesylate (GX15-070) purchased from Selleck.
HUH6 cells (C-H) were incubated with and without 10 ng/ml TNF-α and obatoclax at 0.1, 0.3 uM. Fewer mitochondria with an intact membrane potential were observed in JC-1 staining when obatoclax and TNF-α were added to the culture. Reddish points indicate the aggregation of JC-1 in intact mitochondria, and missing of reddish points indicate the start of apoptosis.

Exp Cell Res 2014 322, 217-25. Obatoclax Mesylate (GX15-070) purchased from Selleck.

Cell proliferation assays were carried out in SET-2 cells treated with increasing concentrations of NVP-BSK805 (empty triangles/solid line), obatoclax (filled squares/dotted line) or NVP-BSK805 in combination with a fixed obatoclax concentration of 700 nM (filled triangles/stippled line) for 72 hours.

BMC Cancer 2011 11, 24. Obatoclax Mesylate (GX15-070) purchased from Selleck.
MEF cells were treated for 24 hours with the Bcl-2 antagonists Obatoclax Mesylate at the indicated doses.Acute survival was monitored by replacing the drug-containing media with normal media and incubating the cells until visible colonies formed.Clonogenic survival is expressed relative to the numbers of colonies formed following 24 hours incubation in normal media(lacking drugs).

Dr. Christine Hawkins of La Trobe University. Obatoclax Mesylate (GX15-070) purchased from Selleck.

MDB-MA-231 cells were exposed to 30 μM cisplatin in the absence or in thepresence of 1 μM Obatoclax Mesylate .The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

Dr. Zhang of Tianjin Medical University. Obatoclax Mesylate (GX15-070) purchased from Selleck.
Obataclax triggers cell death similarly in parental and ABT-737-resistant cells. Parental and ABT-R cells were treated with obataclax (Nalm-6 and Nalm-6 ABT-R: 10 uM; Reh and Reh ABT-R: 5 uM) for 18 h. (A) Cell viability was determined by trypan blue exclusion assay. (B) Mcl-1, NOXA, Bim, and b-actin as a loading control were analyzed by immunoblot.

Obatoclax Mesylate (GX15-070) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features

Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

Targets

Bcl-2 ^[1]
(Cell-free assay)

0.22 μM(Ki)

In vitro

Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. ^[1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. ^[2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KARPAS-45	M2qwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;lZWlEPTB;MD6wNFAxOzF5IN88US=>	NX;nUmhiW0GQR1XS
SK-MEL-30	NX7V[VVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfQR4oxUUN3ME2wMlAxODN3NTFOwG0>	MUPTRW5ITVJ?
NALM-6	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\scYlUUUN3ME2wMlAxODN3NjFOwG0>	MYXTRW5ITVJ?
KYSE-450	Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHwTWM2OD1yLkCwNFQ3QSEQvF2=	NIrHXHlUSU6JRWK=
BHY	MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\KWGVlUUN3ME2wMlAxODZyMTFOwG0>	NFPTdG1USU6JRWK=
GR-ST	NV;tcG97T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjNd25nUUN3ME2wMlAxODZ2ODFOwG0>	NGC5eXhUSU6JRWK=
786-0	MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTBwMECwO\|c3KM7:TR?=	NV30R2Z4W0GQR1XS
C-33-A	NVfYSWl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwMECwPFQ5KM7:TR?=	M1[y[HNCVkeHUh?=
BHT-101	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTi[VdlUUN3ME2wMlAxOTB4IN88US=>	MlvxV2FPT0WU
EB2	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\EfodKSzVyPUCuNFAyOThizszN	MlexV2FPT0WU
G-361	Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7tTWM2OD1yLkCwNVI1KM7:TR?=	MlTrV2FPT0WU
KE-37	MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTBwMECxNlgh\|ryP	NXuzN5gyW0GQR1XS
MHH-PREB-1	M{i0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjhXHJlUUN3ME2wMlAxOTRizszN	MWnTRW5ITVJ?
MCF7	MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwMECxOVkh\|ryP	NV7VTG9tW0GQR1XS
LOUCY	NUewdYRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwMECxO\|Uh\|ryP	MUXTRW5ITVJ?
EW-7	NEH5VYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnezTWM2OD1yLkCwNVc2KM7:TR?=	NHfUXFhUSU6JRWK=
KYSE-510	M3PCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrsPYFKSzVyPUCuNFAzOzNizszN	NYXwRpp{W0GQR1XS
SK-MEL-3	NWnTV5ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVS0dnhwUUN3ME2wMlAxOjZ2IN88US=>	NWr4PXdsW0GQR1XS
HAL-01	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3oZpEyUUN3ME2wMlAxOjl5IN88US=>	M2m3THNCVkeHUh?=
HCC2998	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnn2TWM2OD1yLkCwN\|M2KM7:TR?=	MmDmV2FPT0WU
A375	NG[zUVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwMECzOUDPxE1?	MYDTRW5ITVJ?
MZ7-mel	NF20NoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\lVJd[UUN3ME2wMlAxOzl7IN88US=>	M1XobXNCVkeHUh?=
SH-4	NF\mWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;YTWM2OD1yLkCwOFE4KM7:TR?=	Ml3PV2FPT0WU
HT-144	M4Du[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjwTWM2OD1yLkCwOFMh\|ryP	NFv6U\|ZUSU6JRWK=
KYSE-140	NGnOdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnEZZBKSzVyPUCuNFA1OzVizszN	MWfTRW5ITVJ?
PSN1	NGThZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLqTWM2OD1yLkCwOFY4KM7:TR?=	NF6zZ2ZUSU6JRWK=
COLO-679	MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfnTWM2OD1yLkCwOFk5KM7:TR?=	NVq0UHl2W0GQR1XS
SW620	MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HibGlEPTB;MD6wNFUyOSEQvF2=	NVmwVVh3W0GQR1XS
HGC-27	NVrYc2RnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXMcFlLUUN3ME2wMlAxPTJ2IN88US=>	MV3TRW5ITVJ?
IGROV-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{juT2lEPTB;MD6wNFYh\|ryP	NHjxfpFUSU6JRWK=
IGR-1	MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfUXJpKSzVyPUCuNFA3ODFizszN	MXXTRW5ITVJ?
EW-1	M1\QN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUL2VWZwUUN3ME2wMlAxPjVzIN88US=>	NGfhPGVUSU6JRWK=
769-P	M3rKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfBRmsyUUN3ME2wMlAxPjd6IN88US=>	NFHmNGNUSU6JRWK=
HN	NXHhb2RuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3y5NWlEPTB;MD6wNFY4QSEQvF2=	NELBZo1USU6JRWK=
SIG-M5	M1nHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTBwMEC3NUDPxE1?	Mn;QV2FPT0WU
IST-MEL1	NILoSm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnVc2szUUN3ME2wMlAxQDF6IN88US=>	MXXTRW5ITVJ?
ST486	NIDlW4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zjfWlEPTB;MD6wNFgzPSEQvF2=	MoDKV2FPT0WU
ES7	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mom3TWM2OD1yLkCwPFQ3KM7:TR?=	M2i0ZXNCVkeHUh?=
GAK	M3rpcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTBwMEC4OFgh\|ryP	NED1PGpUSU6JRWK=
BB30-HNC	M2W4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTBwMEC4OVgh\|ryP	NFS2OpVUSU6JRWK=
IPC-298	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHOSGhKSzVyPUCuNFA6OjdizszN	NETNdmxUSU6JRWK=
NKM-1	M1fKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXUTWM2OD1yLkCwPVczKM7:TR?=	NHPI[3lUSU6JRWK=
RKO	NWLqcolYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlL6TWM2OD1yLkCxNFQ1KM7:TR?=	MmXrV2FPT0WU
ACN	NUHtSVVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TPWGlEPTB;MD6wNVE{OSEQvF2=	M{HKZ3NCVkeHUh?=
SW1417	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HuXmlEPTB;MD6wNVIzPSEQvF2=	MVLTRW5ITVJ?
SR	M1;ybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofhTWM2OD1yLkCxNlM2KM7:TR?=	MXjTRW5ITVJ?
SNG-M	NIXiW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwMEGzNVch\|ryP	MXzTRW5ITVJ?
CAL-12T	M4jicmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vkTGlEPTB;MD6wNVM1PiEQvF2=	MX3TRW5ITVJ?
HSC-3	NHPHOYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjGeIdLUUN3ME2wMlAyOzV3IN88US=>	M1mwPXNCVkeHUh?=
DOHH-2	NYHhR\|BVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWf0bpQ6UUN3ME2wMlAyPDF{IN88US=>	M4jtXnNCVkeHUh?=
NB69	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTBwMEG1OlUh\|ryP	MmPEV2FPT0WU
LC-2-ad	MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3QUZBEUUN3ME2wMlAyPThzIN88US=>	MWrTRW5ITVJ?
RVH-421	M3nvWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTBwMEG2O\|Qh\|ryP	MoTXV2FPT0WU
TGW	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rjb2lEPTB;MD6wNVc{QSEQvF2=	M3TqNHNCVkeHUh?=
HCC1569	NX6xcXVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PYXWlEPTB;MD6wNVc6PyEQvF2=	NF\u[\|BUSU6JRWK=
CAL-85-1	NU\OUW0yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTBwMEG4N\|Ih\|ryP	NGfne5RUSU6JRWK=
RPMI-8402	NYfjUmNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\wUZRKSzVyPUCuNFE5PThizszN	NYjDO\|dZW0GQR1XS
THP-1	MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jVU2lEPTB;MD6wNVk6QCEQvF2=	Mmf4V2FPT0WU
ONS-76	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwMEKwN\|Yh\|ryP	NEjyWI5USU6JRWK=
A2780	NY\PWZBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTsTWM2OD1yLkCyNFc6KM7:TR?=	MULTRW5ITVJ?
RPMI-2650	NUT3ZmRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwMEKyPVYh\|ryP	Ml73V2FPT0WU
MEL-HO	MknwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwMEKzOFgh\|ryP	M3XlOnNCVkeHUh?=
MC-CAR	NGTQc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFv3UFNKSzVyPUCuNFI{PTZizszN	MnzSV2FPT0WU
HSC-2	M{P2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml:2TWM2OD1yLkCyOFY3KM7:TR?=	MnHvV2FPT0WU
MEL-JUSO	NHXsenpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkD2TWM2OD1yLkCyOFc{KM7:TR?=	Ml;MV2FPT0WU
CAL-62	MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7ofVc3UUN3ME2wMlAzPjB{IN88US=>	MWrTRW5ITVJ?
DMS-273	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwMEK4OFch\|ryP	MmqyV2FPT0WU
S-117	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rxW2lEPTB;MD6wNlkxPiEQvF2=	Mn\kV2FPT0WU
SUP-T1	M3XwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPpNZhlUUN3ME2wMlAzQTR7IN88US=>	MV;TRW5ITVJ?
MZ2-MEL	NHz3SpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTBwMEK5OVkh\|ryP	MY\TRW5ITVJ?
KYSE-270	NGXpW3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTVTWM2OD1yLkCyPVc3KM7:TR?=	M{PpVnNCVkeHUh?=
CMK	NHrOWWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwMEOwNlMh\|ryP	NFrLUVhUSU6JRWK=
8505C	NYjkT\|lWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXwTWM2OD1yLkCzNFQh\|ryP	M4rCVXNCVkeHUh?=
NUGC-3	MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzGTWM2OD1yLkCzNFQ5KM7:TR?=	MkSxV2FPT0WU
A101D	NXzrWWpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTBwMEOwOVUh\|ryP	NW\OV2hbW0GQR1XS
G-401	M13mWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7QcVRKSzVyPUCuNFMxQTNizszN	Mn;tV2FPT0WU
OVCAR-8	MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nGT2lEPTB;MD6wN\|ExPyEQvF2=	NEPkZphUSU6JRWK=
IMR-5	M3ywS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYr6T2V2UUN3ME2wMlA{OjR2IN88US=>	M2rSd3NCVkeHUh?=
DoTc2-4510	NYnRVlBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DGdWlEPTB;MD6wN\|M6OyEQvF2=	NGjEOYdUSU6JRWK=
HOS	M13JV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIOx[YlKSzVyPUCuNFM1PzNizszN	MknqV2FPT0WU
HEC-1	NEDPTGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPPTWM2OD1yLkCzOlgh\|ryP	M4mzXHNCVkeHUh?=
SW756	NXXOXIlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYq4ZWRPUUN3ME2wMlA{QDJzIN88US=>	NXrRZmxSW0GQR1XS
NCI-H64	NWfKXFJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfmRpg3UUN3ME2wMlA{QDR{IN88US=>	MVLTRW5ITVJ?
EW-16	NVnNVmxpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTBwMEO5NFkh\|ryP	NXmweXh5W0GQR1XS
CAL-51	NV[3PGFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwMESwNFUh\|ryP	MojhV2FPT0WU
KYSE-150	NYP0O3JXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwMESwNVEh\|ryP	M13tW3NCVkeHUh?=
SW1710	MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwMESwNVgh\|ryP	M{nOVnNCVkeHUh?=
HuP-T4	M2izcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nOUWlEPTB;MD6wOFEyQCEQvF2=	NXPUS4ZwW0GQR1XS
LB373-MEL-D	M4L0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzQTWM2OD1yLkC0NlMzKM7:TR?=	MXrTRW5ITVJ?
EW-13	M123S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYK5NVBLUUN3ME2wMlA1PDB4IN88US=>	NF:zNJZUSU6JRWK=
HT-29	MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\UVGlEPTB;MD6wOFQ6KM7:TR?=	NXPQbYhvW0GQR1XS
SCC-25	M13WXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;RTWM2OD1yLkC0OFk1KM7:TR?=	NFjSbW5USU6JRWK=
REH	NVTvblRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITUdHVKSzVyPUCuNFQ3OzVizszN	M4rKSHNCVkeHUh?=
L-363	NIn0WppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTBwMES2O\|kh\|ryP	NHHiOXFUSU6JRWK=
NCI-H1770	NYm5fWlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfRVnhKSzVyPUCuNFQ3QTdizszN	NUXzeHBmW0GQR1XS
CHL-1	M1iwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTBwMES4OVch\|ryP	NGSxRmhUSU6JRWK=
ES1	MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTBwMES4PFUh\|ryP	MV7TRW5ITVJ?
SCC-15	NYrPNFRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwMES5NFIh\|ryP	M2LRVXNCVkeHUh?=
MRK-nu-1	MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMES5N\|Yh\|ryP	NYrVWHpHW0GQR1XS
PF-382	NUe0O\|VOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLzUnF1UUN3ME2wMlA1QTN7IN88US=>	NWXveXROW0GQR1XS
COLO-680N	MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\UTWM2OD1yLkC1NFQ4KM7:TR?=	NFv4N3ZUSU6JRWK=
LK-2	NIXVTWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXSTWM2OD1yLkC1NFY{KM7:TR?=	NUPMVYptW0GQR1XS
NCI-H2342	NGjYTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{[2VGlEPTB;MD6wOVEyPyEQvF2=	NXLkRW92W0GQR1XS
HMV-II	M3noWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmT1TWM2OD1yLkC1NlM6KM7:TR?=	MX;TRW5ITVJ?
PC-14	M{W4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33NVWlEPTB;MD6wOVI2OiEQvF2=	Mn3GV2FPT0WU
COLO-320-HSR	NYnQ[Hh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrkUmlKSzVyPUCuNFUzQDlizszN	MUPTRW5ITVJ?
697	NYHh[IFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7qXo9QUUN3ME2wMlA2OzJ\|IN88US=>	MYjTRW5ITVJ?
NEC8	M{mwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwMEW1PUDPxE1?	M4qwO3NCVkeHUh?=
LCLC-97TM1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\RS2lEPTB;MD6wOVU6PCEQvF2=	NGnIV4pUSU6JRWK=
Daoy	NHm0R4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnOTWM2OD1yLkC1OlE3KM7:TR?=	NUTUNmMzW0GQR1XS
ETK-1	NHq5cGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwMEW2O\|Ih\|ryP	MX3TRW5ITVJ?
A388	MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDoTWM2OD1yLkC1Olk2KM7:TR?=	MlW5V2FPT0WU
COLO-205	NX31fnpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjhTWM2OD1yLkC1O\|E3KM7:TR?=	NFy1bWFUSU6JRWK=
SK-PN-DW	NHGzWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPaeFFpUUN3ME2wMlA2PzJ7IN88US=>	MnzwV2FPT0WU
SF268	NWn4cY1rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrF[HVFUUN3ME2wMlA2PzV4IN88US=>	NFvPVoVUSU6JRWK=
OCI-AML2	NGnId\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\sTFF1UUN3ME2wMlA2Pzd5IN88US=>	MlfwV2FPT0WU
GAMG	MnTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfoSVhKSzVyPUCuNFU5KM7:TR?=	NIfqcINUSU6JRWK=
BCPAP	NXS3VnNpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jwcWlEPTB;MD6wOVg6OiEQvF2=	MV7TRW5ITVJ?
BC-1	M1;GcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jENWlEPTB;MD6wOlAzOiEQvF2=	MljTV2FPT0WU
IA-LM	NHzJZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUOxUoZVUUN3ME2wMlA3ODV\|IN88US=>	MVrTRW5ITVJ?
NCI-H1299	NXmydJZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzvOI5zUUN3ME2wMlA3OTNizszN	MnPvV2FPT0WU
COR-L23	MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLFTWM2OD1yLkC2NVM1KM7:TR?=	MnmxV2FPT0WU
KYSE-180	NVT4XZVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7MUpNKSzVyPUCuNFYyPDJizszN	MVzTRW5ITVJ?
LOXIMVI	Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnryTWM2OD1yLkC2NVg5KM7:TR?=	MkC5V2FPT0WU
BL-41	NHHVVWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nmTGlEPTB;MD6wOlIyQSEQvF2=	NIHYdFZUSU6JRWK=
BL-70	NV7P[5VYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTBwME[zNFIh\|ryP	MWTTRW5ITVJ?
NOS-1	MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3K3bmlEPTB;MD6wOlQyOSEQvF2=	MW\TRW5ITVJ?
NB13	M1Po[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\xTWM2OD1yLkC2OFIyKM7:TR?=	NWLaOXY2W0GQR1XS
CAL-27	MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwME[0OlQh\|ryP	MXvTRW5ITVJ?
CA46	MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\PZZBKUUN3ME2wMlA3PTN5IN88US=>	M{HHenNCVkeHUh?=
SW962	NIW4VHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwME[1Olkh\|ryP	NFPvT3JUSU6JRWK=
NCI-H226	M4rBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rZU2lEPTB;MD6wOlY{OiEQvF2=	NXrLOYc6W0GQR1XS
KYSE-70	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTBwME[5OFUh\|ryP	M3nFcnNCVkeHUh?=
Daudi	NWjI[o5PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{K0VmlEPTB;MD6wO\|A5OSEQvF2=	NW\vc41QW0GQR1XS
SW626	NHLKfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Moi1TWM2OD1yLkC3NlA1KM7:TR?=	MWPTRW5ITVJ?
ESS-1	MojrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTBwMEeyOFYh\|ryP	MlfVV2FPT0WU
YT	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\NTWM2OD1yLkC3N\|Q2KM7:TR?=	NFHYe29USU6JRWK=
P12-ICHIKAWA	M3TMTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPHT4NKSzVyPUCuNFc{PDlizszN	MWHTRW5ITVJ?
BxPC-3	NGHyZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13aS2lEPTB;MD6wO\|Q2QCEQvF2=	MXjTRW5ITVJ?
CTV-1	NXPTRlhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnmTWM2OD1yLkC3OVE4KM7:TR?=	NXrTTo5GW0GQR1XS
MLMA	MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwMEe1N\|Qh\|ryP	MmjkV2FPT0WU
WSU-NHL	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTBwMEe1OVQh\|ryP	MXvTRW5ITVJ?
CTB-1	Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7OXpppUUN3ME2wMlA4PTh6IN88US=>	NFGzNpZUSU6JRWK=
MMAC-SF	M2P3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml22TWM2OD1yLkC3OlY5KM7:TR?=	MUPTRW5ITVJ?
8-MG-BA	Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml[zTWM2OD1yLkC3PFAyKM7:TR?=	Ml\CV2FPT0WU
NCI-H358	Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTBwMEe4O\|kh\|ryP	NHrU[nJUSU6JRWK=
BFTC-905	MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HvNWlEPTB;MD6wO\|kxQSEQvF2=	M1XVXHNCVkeHUh?=
NCI-H727	M1;iO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTBwMEiwOVMh\|ryP	NW\Ec4ZZW0GQR1XS
CHP-212	NFfKXVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3njcWlEPTB;MD6wPFA6PSEQvF2=	Mm\xV2FPT0WU
HOP-62	NF3LbodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fWUmlEPTB;MD6wPFI1PSEQvF2=	MWfTRW5ITVJ?
CESS	M1nhWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLhXGVKSzVyPUCuNFgzPjlizszN	NXq1[GxQW0GQR1XS
HuCCT1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTDTWM2OD1yLkC4N\|M{KM7:TR?=	NWfYbpN3W0GQR1XS
DEL	NH3pWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnINnRKSzVyPUCuNFg{PDdizszN	M4[0WHNCVkeHUh?=
5637	NHWyNIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTBwMEizOlch\|ryP	M1m3SXNCVkeHUh?=
RS4-11	NYPFNo94T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PDb2lEPTB;MD6wPFQ6PyEQvF2=	M4X5bnNCVkeHUh?=
KURAMOCHI	M4LUZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37vWmlEPTB;MD6wPFUxQSEQvF2=	MUHTRW5ITVJ?
A427	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTBwMEi1NVIh\|ryP	MnvIV2FPT0WU
A3-KAW	NGTvb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkGzTWM2OD1yLkC4OVY3KM7:TR?=	MVfTRW5ITVJ?
LS-123	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH36TpBKSzVyPUCuNFg4OTlizszN	M3q2dXNCVkeHUh?=
LoVo	Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjtUllKSzVyPUCuNFg4OiEQvF2=	NYexfGFJW0GQR1XS
PA-1	NX\6[GR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTBwMEi3Olkh\|ryP	M1;BU3NCVkeHUh?=
CP50-MEL-B	Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTBwMEi3PVMh\|ryP	MkO0V2FPT0WU
A431	M{Tjcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nnV2lEPTB;MD6wPFgxOSEQvF2=	M17qOXNCVkeHUh?=
HCT-116	NGSxXHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofTTWM2OD1yLkC4PFAzKM7:TR?=	NWOxV2s1W0GQR1XS
A4-Fuk	Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnZc41KSzVyPUCuNFg6PDdizszN	MmDvV2FPT0WU
RPMI-6666	NH;uRWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTBwMEi5Olch\|ryP	NHTOSWdUSU6JRWK=
Calu-6	M3r6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17xTWlEPTB;MD6wPVAzQSEQvF2=	MULTRW5ITVJ?
KMOE-2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwMEmwN\|kh\|ryP	MYTTRW5ITVJ?
A704	M{TYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfHTWM2OD1yLkC5NVUh\|ryP	NUjUUmhkW0GQR1XS
HO-1-N-1	M2XmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlG4TWM2OD1yLkC5NlQ6KM7:TR?=	NEeyW2JUSU6JRWK=
NCI-H2122	M3TGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnmV5BKSzVyPUCuNFk{PzhizszN	MnvmV2FPT0WU
U-698-M	M{PmO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrETWM2OD1yLkC5OFA6KM7:TR?=	MYfTRW5ITVJ?
IST-SL2	NIDrVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDOWYpKSzVyPUCuNFk1PjhizszN	MkOzV2FPT0WU
TE-10	NIrsRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PVVmlEPTB;MD6wPVU5PCEQvF2=	M4\0[HNCVkeHUh?=
PANC-03-27	M{XGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfKcG5PUUN3ME2wMlA6PjdzIN88US=>	MlnhV2FPT0WU
KYSE-410	NIfaUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{H6[2lEPTB;MD6wPVc6PyEQvF2=	NEnTc4lUSU6JRWK=
TE-8	M2jNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTBwMEm4PFUh\|ryP	NV7mblVJW0GQR1XS
MN-60	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1r0bWlEPTB;MD6wPVg6PyEQvF2=	M2LGfXNCVkeHUh?=
NCI-H460	NYGxd5Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvITWM2OD1yLkGwNFkh\|ryP	Mor1V2FPT0WU
LB771-HNC	NYn4elh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrlc2RtUUN3ME2wMlExOjV3IN88US=>	MlT0V2FPT0WU
ES4	NV7zO5N2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwMUCyOlQh\|ryP	MnKyV2FPT0WU
HUTU-80	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHe1U5pKSzVyPUCuNVA{PjVizszN	MmqyV2FPT0WU
647-V	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGj5ZmRKSzVyPUCuNVA1ODhizszN	MnPMV2FPT0WU
HTC-C3	MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PiN2lEPTB;MD6xNFQ{OiEQvF2=	NF7jVoNUSU6JRWK=
NTERA-S-cl-D1	MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DLfWlEPTB;MD6xNFQ1QCEQvF2=	MnfpV2FPT0WU
A2058	NXX6eHJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTBwMUC2OVUh\|ryP	M1HSenNCVkeHUh?=
MZ1-PC	NHL6N\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTBwMUC4N{DPxE1?	M1;MSnNCVkeHUh?=
J82	NWXqOo5XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTBwMUC4PFQh\|ryP	Ml3DV2FPT0WU
ARH-77	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDqTWM2OD1yLkGxJO69VQ>?	NFjNe5lUSU6JRWK=
Ca9-22	MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17FemlEPTB;MD6xNVEzQCEQvF2=	NFTOU2xUSU6JRWK=
NCI-H1648	M4\IWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwMUGyPFYh\|ryP	MY\TRW5ITVJ?
MC116	M4\SZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvhNnRKSzVyPUCuNVE{OzdizszN	MXzTRW5ITVJ?
EoL-1-cell	Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\tNoxKSzVyPUCuNVE1PjdizszN	MoDvV2FPT0WU
PANC-10-05	NI[0c3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HkOWlEPTB;MD6xNVQ6OSEQvF2=	M1fkbXNCVkeHUh?=
SF539	NFLocZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLqeXVqUUN3ME2wMlEyPjF4IN88US=>	M3\YZnNCVkeHUh?=
ES8	MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2j3WmlEPTB;MD6xNVY{OyEQvF2=	NUHQeWZWW0GQR1XS
NCI-H810	NIPRT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLCTWM2OD1yLkGxOlY1KM7:TR?=	NYj4RYN2W0GQR1XS
J-RT3-T3-5	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn[1TWM2OD1yLkGxO\|Uh\|ryP	MX3TRW5ITVJ?
NY	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDXbVBKSzVyPUCuNVE5OTdizszN	M3W3eXNCVkeHUh?=
NCI-SNU-1	NUfvWYZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3e5d2lEPTB;MD6xNlE1QCEQvF2=	NHHoO2JUSU6JRWK=
EFM-19	NXy1XZpiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGizV\|NKSzVyPUCuNVI{PzRizszN	MkjlV2FPT0WU
HCC1806	M4TleGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTBwMUKzPFMh\|ryP	MoT5V2FPT0WU
HCE-T	M{PLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWf5VplTUUN3ME2wMlEzPTNzIN88US=>	NXSyVmtNW0GQR1XS
HT-1376	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1S3PGlEPTB;MD6xNlY3QCEQvF2=	MX\TRW5ITVJ?
BE-13	NX3aV2dsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HrNmlEPTB;MD6xNlg3PiEQvF2=	NHXzeY9USU6JRWK=
NCI-H520	Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTBwMUK4Olch\|ryP	MnzIV2FPT0WU
SK-MES-1	Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrrc4JLUUN3ME2wMlEzQTF\|IN88US=>	MmLEV2FPT0WU
SNU-423	M1LhPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPkTWM2OD1yLkGyPVE1KM7:TR?=	MYXTRW5ITVJ?
Ramos-2G6-4C10	NUL5OXpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfPUIVzUUN3ME2wMlEzQTF4IN88US=>	NVT5b5l3W0GQR1XS
EW-18	M1PwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTBwMUOwNlYh\|ryP	NH2zOnFUSU6JRWK=
NCI-H2087	NIH6TGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DySGlEPTB;MD6xN\|AzPyEQvF2=	NUK1PWhJW0GQR1XS
COLO-792	MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3myU2lEPTB;MD6xN\|E3PSEQvF2=	NWD2RoZnW0GQR1XS
QIMR-WIL	M3[4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3XTWM2OD1yLkGzNlI{KM7:TR?=	NEfyVmtUSU6JRWK=
ACHN	NITVcmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPtW5g1UUN3ME2wMlE{OjR5IN88US=>	MnPDV2FPT0WU
RPMI-8866	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTBwMUOyOlEh\|ryP	MWnTRW5ITVJ?
SK-LU-1	M2C4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHHc3lLUUN3ME2wMlE{PDR7IN88US=>	M1TmeHNCVkeHUh?=
SK-UT-1	NEfBOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTBwMUO2Nlgh\|ryP	Mom4V2FPT0WU
MFE-296	NYPrUVVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTSTWM2OD1yLkGzPFY1KM7:TR?=	NVOwOnhjW0GQR1XS
RD	NX3DRo0xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HoZ2lEPTB;MD6xN\|k6PyEQvF2=	NEnOUnJUSU6JRWK=
LS-411N	NU\pNllPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4mwV2lEPTB;MD6xOFI6PSEQvF2=	NXW3O3RIW0GQR1XS
NCI-H747	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTBwMUSzJO69VQ>?	M1;FNHNCVkeHUh?=
ES6	NFLBXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTBwMUSzOkDPxE1?	MlewV2FPT0WU
TE-1	M1jpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYX3PGk2UUN3ME2wMlE1PDB5IN88US=>	NIjj[mdUSU6JRWK=
SJSA-1	M325Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEiwPXhKSzVyPUCuNVQ4ODdizszN	M1TweXNCVkeHUh?=
NCI-H1355	MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nJT2lEPTB;MD6xOVI6OyEQvF2=	M{HqfHNCVkeHUh?=
HEL	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFT3[YhKSzVyPUCuNVU1PDdizszN	MonlV2FPT0WU
639-V	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUC4SopuUUN3ME2wMlE2PTl4IN88US=>	M1;2SXNCVkeHUh?=
AN3-CA	Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvwOHFKSzVyPUCuNVU3OzlizszN	MnXmV2FPT0WU
SK-MEL-2	NV;iN3dyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGexZmRKSzVyPUCuNVU3PjhizszN	NYDHfFJKW0GQR1XS
SW872	NFnONGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrUO5N2UUN3ME2wMlE3ODR{IN88US=>	MUnTRW5ITVJ?
DU-4475	NYO1WGxyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLDU\|ExUUN3ME2wMlE3OTZ{IN88US=>	NYDYWHYxW0GQR1XS
YKG-1	NUnYWFl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnRe5lQUUN3ME2wMlE3Ojd\|IN88US=>	MlLUV2FPT0WU
GT3TKB	NXPnZo4yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPoS5ZKSzVyPUCuNVYzQDNizszN	M4H3WHNCVkeHUh?=
GB-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofnTWM2OD1yLkG2OFI1KM7:TR?=	Mn[1V2FPT0WU
KARPAS-422	NF\ONG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHmyW4VKSzVyPUCuNVY2PzRizszN	MUXTRW5ITVJ?
ATN-1	MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwMU[2OVYh\|ryP	MUHTRW5ITVJ?
HLE	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfsSGN2UUN3ME2wMlE3QDd5IN88US=>	NGHUfG9USU6JRWK=
D-542MG	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPkfWhKSzVyPUCuNVY6QDZizszN	MlzVV2FPT0WU
EB-3	NVK2XJlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPBTXVKSzVyPUCuNVc{OSEQvF2=	MYTTRW5ITVJ?
HCC1143	NVW4XHpOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjaWmlbUUN3ME2wMlE4Ozl4IN88US=>	MX3TRW5ITVJ?
DJM-1	NETxRoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF60cIlKSzVyPUCuNVc1PTFizszN	NUfl[FI2W0GQR1XS
BT-474	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHKZY9KSzVyPUCuNVc1QDlizszN	NVTpWWloW0GQR1XS
BB65-RCC	NG\lNFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkX4TWM2OD1yLkG3OVQ2KM7:TR?=	NXHn[\|FtW0GQR1XS
NCI-H292	M{n2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPwdXNKSzVyPUCuNVc3ODFizszN	M4nLbXNCVkeHUh?=
MKN28	NGXmfWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfR[HRKSzVyPUCuNVc3PTNizszN	MXPTRW5ITVJ?
TK10	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUL6So55UUN3ME2wMlE4PzB{IN88US=>	MUjTRW5ITVJ?
TYK-nu	M3HsVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3ZcIRKSzVyPUCuNVc6PDlizszN	NIPZdZhUSU6JRWK=
8305C	MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\iU29KSzVyPUCuNVc6PzFizszN	MnnqV2FPT0WU
MV-4-11	M1fFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHGTWM2OD1yLkG3PVc4KM7:TR?=	MofiV2FPT0WU
NCI-H522	NYXaZotFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULyO254UUN3ME2wMlE5ODl2IN88US=>	NH7acphUSU6JRWK=
Hs-578-T	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTBwMUiyPVIh\|ryP	MkfmV2FPT0WU
LCLC-103H	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwMUi1Nlch\|ryP	NGDBWY1USU6JRWK=
MHH-ES-1	NXXXTXI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3Sz[2lEPTB;MD6xPFYzQSEQvF2=	Mmr4V2FPT0WU
NCI-H441	Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\s[odKSzVyPUCuNVkyPDhizszN	MYPTRW5ITVJ?
AM-38	NGPqPHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvrTWM2OD1yLkG5NlI2KM7:TR?=	NV;JVHZHW0GQR1XS
SW1783	NG\SOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXuTG9KSzVyPUCuNVk{ODVizszN	NI\Ne45USU6JRWK=
SK-HEP-1	NFTteppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWW0R4M3UUN3ME2wMlE6PjN5IN88US=>	NXfEO\|c{W0GQR1XS
OAW-28	NHvLWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\nTWM2OD1yLkKwNVc5KM7:TR?=	NHH0b3NUSU6JRWK=
TE-15	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;2SHJ7UUN3ME2wMlIxOjV{IN88US=>	MnzMV2FPT0WU
HCE-4	M{DaXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfNOHdpUUN3ME2wMlIxOjh2IN88US=>	NEnpeGhUSU6JRWK=
JiyoyeP-2003	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVeyeIhvUUN3ME2wMlIxOzN4IN88US=>	NIHH[lRUSU6JRWK=
OVCAR-4	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwMkC2Nlgh\|ryP	NF7tZnZUSU6JRWK=
SNU-449	NYTPSYdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;PNmlEPTB;MD6yNFc6PyEQvF2=	M2fn[XNCVkeHUh?=
SBC-5	NYX5UG9rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEm2O5lKSzVyPUCuNlEzOTVizszN	Mn7wV2FPT0WU
T84	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTBwMkGyOFgh\|ryP	NF\6VpdUSU6JRWK=
LP-1	NEPteJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXZTWM2OD1yLkKxN\|AzKM7:TR?=	NYDVc2JJW0GQR1XS
MG-63	NG\6TYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHPOHhKSzVyPUCuNlE{QDJizszN	M{npXnNCVkeHUh?=
OAW-42	M2DKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwMkG0O\|gh\|ryP	Mn7BV2FPT0WU
L-540	NFHpOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwMkG1PVgh\|ryP	NHHDNnJUSU6JRWK=
RH-1	NYO2c3FHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTBwMkKyOFIh\|ryP	Mmq0V2FPT0WU
HCT-15	NHTDUoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jhZ2lEPTB;MD6yNlQ5PCEQvF2=	MXvTRW5ITVJ?
OCUB-M	M1;iU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mkm2TWM2OD1yLkKyOFg5KM7:TR?=	Ml;yV2FPT0WU
GP5d	MnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnpN\|lKSzVyPUCuNlI2OjhizszN	NVzBcI55W0GQR1XS
NCI-H2030	MorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3flXGlEPTB;MD6yNlc{PCEQvF2=	MofoV2FPT0WU
ML-2	NXrEZWlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHn4OnFKSzVyPUCuNlI5QDlizszN	NEnC[5ZUSU6JRWK=
CAL-39	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTBwMkK5N\|Yh\|ryP	MmPvV2FPT0WU
MIA-PaCa-2	NVnjZ\|VDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmX1TWM2OD1yLkKzNlg4KM7:TR?=	M{fsVHNCVkeHUh?=
TE-9	NWX6NWJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIL5dIRKSzVyPUCuNlM{OiEQvF2=	NIjuSVdUSU6JRWK=
LB2518-MEL	NFnkWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDjTWM2OD1yLkKzN\|czKM7:TR?=	NHnJXmpUSU6JRWK=
DB	Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3no[GlEPTB;MD6yN\|Q{QCEQvF2=	M3HJ[nNCVkeHUh?=
NCI-H596	MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17tU2lEPTB;MD6yN\|U4OSEQvF2=	M4njR3NCVkeHUh?=
SW1990	MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzHNIpFUUN3ME2wMlI{QTR4IN88US=>	MWDTRW5ITVJ?
P30-OHK	M2LKVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTBwMkSwOUDPxE1?	NI\Jd\|lUSU6JRWK=
ALL-PO	NU\HUJRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjqenNDUUN3ME2wMlI1OTZ7IN88US=>	MXjTRW5ITVJ?
Saos-2	M3Pp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlP4TWM2OD1yLkK0OVcyKM7:TR?=	M1jSbHNCVkeHUh?=
MFH-ino	NYHuNZpRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrDR\|hKSzVyPUCuNlQ3QTJizszN	MoTGV2FPT0WU
OE33	MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PFTmlEPTB;MD6yOVEyKM7:TR?=	NYHS[nVCW0GQR1XS
Calu-3	M3X0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2Xy[GlEPTB;MD6yOVI6PyEQvF2=	MX7TRW5ITVJ?
HT	NGTaUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTrUmFKSzVyPUCuNlU3OjFizszN	MmPaV2FPT0WU
LXF-289	NXTTcYZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTBwMkW5PFQh\|ryP	MnfOV2FPT0WU
KGN	MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTBwMk[wPFkh\|ryP	NYDicVNRW0GQR1XS
NCI-H1417	NX3HNpl3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HlN2lEPTB;MD6yOlUzPCEQvF2=	NXW0em8{W0GQR1XS
SF126	NGq0dGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwMkezNFIh\|ryP	M{HxRnNCVkeHUh?=
SAS	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLyS4R{UUN3ME2wMlI4OzB6IN88US=>	M3vydnNCVkeHUh?=
22RV1	MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwMkezO\|gh\|ryP	NU\Fc2g3W0GQR1XS
GI-1	NE[x[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zreGlEPTB;MD6yO\|Q5PyEQvF2=	MV\TRW5ITVJ?
ES3	NVPYPHVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnS0TWM2OD1yLkK3O\|Y{KM7:TR?=	MonLV2FPT0WU
NB1	M{DlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\ReFFWUUN3ME2wMlI4QDd4IN88US=>	NHvCfW1USU6JRWK=
NCI-H650	Mnv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwMkizNFIh\|ryP	MUHTRW5ITVJ?
IST-MES1	M4PSTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTBwMki1OVQh\|ryP	NES0UVhUSU6JRWK=
UM-UC-3	M2[3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1i1TWlEPTB;MD6yPVE1KM7:TR?=	NH3zeoZUSU6JRWK=
CAL-120	NIjrSoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\NT2lEPTB;MD6yPVY{OSEQvF2=	NWrNVFdIW0GQR1XS
UACC-62	M4LTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTBwM{CyOFEh\|ryP	M{faV3NCVkeHUh?=
TE-11	M{\1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfUbIJoUUN3ME2wMlMxOjR7IN88US=>	NHuyNnJUSU6JRWK=
MKN1	NFzPOXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTBwM{CzOkDPxE1?	MVjTRW5ITVJ?
KS-1	NWjUN4pyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTBwM{C1NlYh\|ryP	NWP0Z5diW0GQR1XS
GCIY	NWfT[VlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXkb5ZPUUN3ME2wMlMyODB{IN88US=>	MoHHV2FPT0WU
OVCAR-5	M1f6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LWZ2lEPTB;MD6zNVExPiEQvF2=	Mn;KV2FPT0WU
U-266	NGWzS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTBwM{GxOFch\|ryP	M2PRbHNCVkeHUh?=
Calu-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXofYJyUUN3ME2wMlMyOjh7IN88US=>	M1LjSXNCVkeHUh?=
SK-LMS-1	NHHsc4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlezTWM2OD1yLkOxOFI6KM7:TR?=	Mni5V2FPT0WU
COLO-741	M3jtWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDzbXZKSzVyPUCuN\|E3OTRizszN	NVXOd4V{W0GQR1XS
RPMI-8226	NIjvSWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPaV\|VKSzVyPUCuN\|E3PDFizszN	NUjKV2JoW0GQR1XS
KM12	M2\xOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2SweGlEPTB;MD6zNVg{KM7:TR?=	MVjTRW5ITVJ?
NMC-G1	MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{KwSWlEPTB;MD6zNVg3KM7:TR?=	MWjTRW5ITVJ?
SJRH30	Mnv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTBcmVWUUN3ME2wMlMzODV{IN88US=>	NX;zN5dJW0GQR1XS
COR-L105	M4HHfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LNbGlEPTB;MD6zNlIyQCEQvF2=	MX3TRW5ITVJ?
IM-9	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIr4ZlFKSzVyPUCuN\|MxOjFizszN	MWXTRW5ITVJ?
TE-12	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnCT5Z[UUN3ME2wMlM{OzF5IN88US=>	MXzTRW5ITVJ?
KG-1	NHzCZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\2VmtKSzVyPUCuN\|M1OzJizszN	MliyV2FPT0WU
U251	MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfoTWM2OD1yLkOzOFU3KM7:TR?=	MUHTRW5ITVJ?
EFO-27	M2rMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTBwM{O5OVEh\|ryP	MXjTRW5ITVJ?
EW-24	M1PuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkSyTWM2OD1yLkOzPVg1KM7:TR?=	NIP1OoVUSU6JRWK=
SF295	NXLxXG85T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jWZ2lEPTB;MD6zN\|k6QSEQvF2=	MU\TRW5ITVJ?
MC-IXC	MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojDTWM2OD1yLkO0OUDPxE1?	MkfVV2FPT0WU
NCI-H2405	MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7yeFdKSzVyPUCuN\|Q4OzJizszN	NEnFTWhUSU6JRWK=
NCI-H2009	M1zrd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHr5SlRKSzVyPUCuN\|Q4OzlizszN	NGniXmpUSU6JRWK=
LB1047-RCC	NFPxVnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFK1dpRKSzVyPUCuN\|U5OTVizszN	NX;LOZNGW0GQR1XS
KNS-81-FD	NXj4RpM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILwcJNKSzVyPUCuN\|Y3PjdizszN	NXTwOo9vW0GQR1XS
HOP-92	M4nqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjmTWM2OD1yLkO2PFMh\|ryP	MVLTRW5ITVJ?
L-428	M3PWbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2eycmlEPTB;MD6zO\|AyPiEQvF2=	Mmm3V2FPT0WU
C3A	M4HFbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvLTWM2OD1yLkO3N\|c6KM7:TR?=	Mlj5V2FPT0WU
NCI-H1792	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwM{e2OVUh\|ryP	NFvVSnRUSU6JRWK=
HuH-7	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYO1SW1WUUN3ME2wMlM4QTFizszN	NVni[2dxW0GQR1XS
AGS	NFuxbmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInmZ3VKSzVyPUCuN\|g3OzhizszN	M3zHXnNCVkeHUh?=
HT-1197	M2PFfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTBwM{m0OkDPxE1?	M3jjU3NCVkeHUh?=
CGTH-W-1	M1zx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTBwM{m5NVMh\|ryP	NHTrR4xUSU6JRWK=
KNS-42	NXfQVGxNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\vTWM2OD1yLkSwNFQ2KM7:TR?=	M3jQXnNCVkeHUh?=
HuO-3N1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrTTWM2OD1yLkSwNFU2KM7:TR?=	M2rBZnNCVkeHUh?=
VMRC-RCZ	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PDS2lEPTB;MD60NFMxOyEQvF2=	M2nMbnNCVkeHUh?=
SW954	MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;TWW5KSzVyPUCuOFA{OzVizszN	M{LEUnNCVkeHUh?=
MES-SA	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTBwNEC1NFUh\|ryP	MorWV2FPT0WU
Ca-Ski	MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPpRZFKSzVyPUCuOFA2OjRizszN	M3fzPXNCVkeHUh?=
SW13	NHPrWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTBwNEC2NlYh\|ryP	NHPIVlVUSU6JRWK=
NCI-H1437	Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXW5e3hUUUN3ME2wMlQxQDB3IN88US=>	NILpZVVUSU6JRWK=
U-118-MG	MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwNEC5NFQh\|ryP	MUDTRW5ITVJ?
NCI-H1734	M2HHbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXToTmdjUUN3ME2wMlQzODF\|IN88US=>	MV;TRW5ITVJ?
HDLM-2	M3;yWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTBwNEKwN\|Mh\|ryP	NYC3b3NxW0GQR1XS
AU565	NHfLS2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvITWM2OD1yLkSyOFY5KM7:TR?=	NX3wbnBbW0GQR1XS
FADU	Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mor6TWM2OD1yLkSyOlQ6KM7:TR?=	Mm\hV2FPT0WU
OS-RC-2	MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HBe2lEPTB;MD60N\|A5OyEQvF2=	M3Tv[HNCVkeHUh?=
CAMA-1	NETUVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTBwNEO2NlYh\|ryP	MX\TRW5ITVJ?
MONO-MAC-6	M3jNWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjVTWM2OD1yLkSzPFQ6KM7:TR?=	MVvTRW5ITVJ?
LB831-BLC	M2X3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwNESzO\|Eh\|ryP	M37JeHNCVkeHUh?=
SW982	M4LM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHkdVFKSzVyPUCuOFQ2OjhizszN	M{f4[HNCVkeHUh?=
SCC-3	MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwNES1O\|kh\|ryP	NIPmUXhUSU6JRWK=
C32	MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PESWlEPTB;MD60OVIzQSEQvF2=	NEnQWYZUSU6JRWK=
BFTC-909	NVvSR49GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7m[\|I5UUN3ME2wMlQ2Ojl7IN88US=>	MkPEV2FPT0WU
MEG-01	NYDQe4N6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHleldKSzVyPUCuOFU{PzNizszN	NHTqPJFUSU6JRWK=
M14	Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfkOY13UUN3ME2wMlQ2QTd7IN88US=>	MkHnV2FPT0WU
MPP-89	NFfOcYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjVVHI6UUN3ME2wMlQ3OjV4IN88US=>	NX21R5FxW0GQR1XS
HCC1937	Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYOyTlJvUUN3ME2wMlQ3Ozh2IN88US=>	M2HlS3NCVkeHUh?=
SW837	NHzqe3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3f2UGlEPTB;MD60OlczOiEQvF2=	NXnO[VZTW0GQR1XS
DU-145	NFLKTW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTBwNE[3Nlkh\|ryP	NF\ySJdUSU6JRWK=
LB996-RCC	M3XyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLxWmlYUUN3ME2wMlQ4ODV2IN88US=>	M1XCdXNCVkeHUh?=
C8166	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTBwNEe0JO69VQ>?	NHjpWVFUSU6JRWK=
MOLT-4	M4\5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LYNmlEPTB;MD60O\|c{PCEQvF2=	NGW1[ZFUSU6JRWK=
DMS-53	NVnadGVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTBwNEe4NFkh\|ryP	M3LldXNCVkeHUh?=
TE-5	NXPRRZlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDpUVRKSzVyPUCuOFg{ODVizszN	NXP3RZBLW0GQR1XS
KYSE-520	M2LXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIK0ZXVKSzVyPUCuOFg{PDNizszN	NXTOepgzW0GQR1XS
Detroit562	MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjrXlhXUUN3ME2wMlQ5QDZizszN	NV\NZ\|BHW0GQR1XS
SIMA	NYe2TlNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LVcmlEPTB;MD60PVQyPyEQvF2=	MkDEV2FPT0WU
NCI-H1651	NFq0[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrPe4hKSzVyPUCuOFk3PyEQvF2=	M3O4T3NCVkeHUh?=
HCC1599	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPJboFKSzVyPUCuOFk6PTVizszN	M1\sN3NCVkeHUh?=
ABC-1	NULMWoRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33PZ2lEPTB;MD61NFQ6PiEQvF2=	NHXYXHlUSU6JRWK=
CAL-33	MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwNUC4OFQh\|ryP	MV3TRW5ITVJ?
OPM-2	Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfDdI9KSzVyPUCuOVA6OzdizszN	NFLYSGJUSU6JRWK=
RPMI-7951	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnoSG5IUUN3ME2wMlUxQTV5IN88US=>	Mlv0V2FPT0WU
HT-1080	MofzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;6U2NXUUN3ME2wMlUyOTF7IN88US=>	NXjJWWwyW0GQR1XS
LC4-1	M1vtS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwNUG0NFMh\|ryP	MlnoV2FPT0WU
OVCAR-3	M2T3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInGOWhKSzVyPUCuOVE2PyEQvF2=	MmrUV2FPT0WU
CAPAN-1	Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXpW\|NUUUN3ME2wMlUzOjh6IN88US=>	Ml[2V2FPT0WU
SK-OV-3	M3TpW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwNUK0N\|Qh\|ryP	M2LvNHNCVkeHUh?=
HuP-T3	MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;zVZVlUUN3ME2wMlUzQDJ5IN88US=>	NXvxZ4s3W0GQR1XS
NCI-H838	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\BTWM2OD1yLkWyPFQ6KM7:TR?=	MV7TRW5ITVJ?
K5	NGjkb5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\2dXhnUUN3ME2wMlU{OjBzIN88US=>	MVLTRW5ITVJ?
CAL-72	NW\VZZZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjPZ3h7UUN3ME2wMlU{Ozh5IN88US=>	NGPrPFNUSU6JRWK=
NH-12	NVS0[VNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwNUO5OVkh\|ryP	MmjtV2FPT0WU
SNB75	NXHrRnVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LUdGlEPTB;MD61OVc{KM7:TR?=	MXTTRW5ITVJ?
BPH-1	NVvOeHQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwNU[zOFQh\|ryP	MYrTRW5ITVJ?
NOMO-1	MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;mUZVxUUN3ME2wMlU3Ozd{IN88US=>	Mn3qV2FPT0WU
G-402	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DzbGlEPTB;MD61OlQ6QSEQvF2=	M1joTHNCVkeHUh?=
NCI-H2052	NYXEW\|VzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTBwNU[3OFEh\|ryP	M{TnV3NCVkeHUh?=
RCM-1	NXPmb2VFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwNUexOlYh\|ryP	MknSV2FPT0WU
COR-L279	M2XBXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfNZXZKSzVyPUCuOVcyQDVizszN	NIC3eWhUSU6JRWK=
A253	Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTBwNUe1NlUh\|ryP	NF7hZoRUSU6JRWK=
SK-MM-2	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTBwNUe2O\|kh\|ryP	NHTWcIFUSU6JRWK=
NCI-H1703	NHfRNFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTBwNUm0Nlch\|ryP	MVnTRW5ITVJ?
UACC-257	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\jNI5KSzVyPUCuOVk1QDdizszN	NWPW[JZoW0GQR1XS
KALS-1	NFy0V3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUK1W2x1UUN3ME2wMlYxODFzIN88US=>	NGL1WVNUSU6JRWK=
ES5	NGnpcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fxW2lEPTB;MD62NFQ5KM7:TR?=	NXXo[nRWW0GQR1XS
MHH-CALL-2	M1m4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXqy[Y1XUUN3ME2wMlYxQDh6IN88US=>	NIS4XnZUSU6JRWK=
ChaGo-K-1	M4XpdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2j0OGlEPTB;MD62NVIzQSEQvF2=	MUDTRW5ITVJ?
TGBC1TKB	MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTBwNkG5PEDPxE1?	M33LR3NCVkeHUh?=
KU-19-19	Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwNkS1PFYh\|ryP	MXPTRW5ITVJ?
COLO-684	NHPX[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml[wTWM2OD1yLk[1OlEyKM7:TR?=	MXLTRW5ITVJ?
LS-1034	NVnhRm5sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vOW2lEPTB;MD62OVgyQSEQvF2=	NUDGR25bW0GQR1XS
RT-112	M4[yfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3wTWM2OD1yLk[2OVg4KM7:TR?=	MnLOV2FPT0WU
Capan-2	NWLvSWRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwNk[2NlIh\|ryP	MYHTRW5ITVJ?
HSC-4	M2PkcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTBwNk[2PVgh\|ryP	MXnTRW5ITVJ?
COLO-824	MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;UTWM2OD1yLk[3PFI{KM7:TR?=	NFTWfGtUSU6JRWK=
NCI-H2170	NWCyOWp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvSTWM2OD1yLk[4NlU5KM7:TR?=	NHfvOHJUSU6JRWK=
GDM-1	NGHMZ5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HvZ2lEPTB;MD62PFQ6PCEQvF2=	NGjOdW1USU6JRWK=
KP-4	M4C2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rnc2lEPTB;MD62PVU4OyEQvF2=	MlnTV2FPT0WU
VA-ES-BJ	NWDYNZUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwNkm5PFYh\|ryP	MWjTRW5ITVJ?
KM-H2	M{K5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTBwN{CwPVEh\|ryP	M1PPXnNCVkeHUh?=
HH	NHOwV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrjeVVKSzVyPUCuO\|A3PjJizszN	M{CzfnNCVkeHUh?=
DK-MG	NUHIWYF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTtTWM2OD1yLkexNFE3KM7:TR?=	NEjGR4FUSU6JRWK=
VM-CUB-1	NH;xVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTBwN{GyOVkh\|ryP	MX3TRW5ITVJ?
COLO-829	M37tTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mny0TWM2OD1yLkexPVg2KM7:TR?=	NEOwPFJUSU6JRWK=
OMC-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnLTWM2OD1yLkeyNVA1KM7:TR?=	M3TicHNCVkeHUh?=
NB12	MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLiNHcxUUN3ME2wMlczPTB2IN88US=>	M2HLUXNCVkeHUh?=
NCI-H28	M4\aPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrCTWM2OD1yLke0NFg{KM7:TR?=	MnXHV2FPT0WU
A673	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLyTWM2OD1yLke1NVc4KM7:TR?=	MlrHV2FPT0WU
LB2241-RCC	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTBwN{[wPFch\|ryP	NEnz[3JUSU6JRWK=
CCRF-CEM	M1jndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7aeYdPUUN3ME2wMlc4ODV{IN88US=>	NELzVo5USU6JRWK=
NCI-H510A	NIXnNpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGSwW3ZKSzVyPUCuO\|cyQDZizszN	NUjXdXRRW0GQR1XS
SW48	NFrWNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoP5TWM2OD1yLke3N\|M{KM7:TR?=	NHHHW5NUSU6JRWK=
NCI-H2081	MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTBwN{ixOFch\|ryP	M2C3UXNCVkeHUh?=
RMG-I	NILZW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{mwVWlEPTB;MD63PFIyOiEQvF2=	MU\TRW5ITVJ?
LU-99A	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwN{i0NVMh\|ryP	MnezV2FPT0WU
KP-N-YS	NWrqR3ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwN{i5NlEh\|ryP	NEDiRllUSU6JRWK=
MDA-MB-231	NUH5fIVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwOECxN\|Eh\|ryP	NVzUbY5DW0GQR1XS
U031	MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwOEG0NlMh\|ryP	MX3TRW5ITVJ?
EVSA-T	M4\ON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLlTWM2OD1yLkixOlczKM7:TR?=	MWXTRW5ITVJ?
MDA-MB-157	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vzUWlEPTB;MD64NlI4OSEQvF2=	M4TsOnNCVkeHUh?=
EHEB	NWDL[XFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml:0TWM2OD1yLkiyNlc3KM7:TR?=	NH[5Zm5USU6JRWK=
KINGS-1	NILZVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEC5cpJKSzVyPUCuPFI2PTVizszN	Mny2V2FPT0WU
23132-87	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTBwOEK4OFMh\|ryP	M1PiNnNCVkeHUh?=
EFO-21	NIr1NWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwOESwPFkh\|ryP	NUPSUIozW0GQR1XS
DOK	NIW2WZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLpTphKSzVyPUCuPFQ5KM7:TR?=	Mm\tV2FPT0WU
NCI-H2171	MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwOES5OkDPxE1?	NF[3c3RUSU6JRWK=
NCI-SNU-5	NYXFcI5tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\6R3V3UUN3ME2wMlg2PTdizszN	NWrxcm5MW0GQR1XS
SK-N-DZ	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Moq4TWM2OD1yLki1PVQ{KM7:TR?=	NWnZTno2W0GQR1XS
SNU-C2B	MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M131bmlEPTB;MD64OlgxOSEQvF2=	MWLTRW5ITVJ?
CP66-MEL	NE\PTZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml[3TWM2OD1yLki3NVEh\|ryP	NFTqb\|dUSU6JRWK=
SN12C	M2X3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\ybWlEPTB;MD64PFY{PyEQvF2=	NIDXXpFUSU6JRWK=
A172	MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2H2S2lEPTB;MD64PFY6QCEQvF2=	NYO2eo45W0GQR1XS
NCI-H2347	M3\WUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTBwOEi3OVMh\|ryP	M4XlO3NCVkeHUh?=
NCI-H2228	NHXDdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37IXWlEPTB;MD64PVM{QSEQvF2=	NWL4UVhvW0GQR1XS
SNU-387	M1zEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTBwOUCyOlQh\|ryP	M4jyZXNCVkeHUh?=
SK-MEL-24	NUjQSpZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHoXYZKSzVyPUCuPVE{PDRizszN	NULV[o9nW0GQR1XS
MDA-MB-468	NXTNbZlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HLVWlEPTB;MD65NVc{KM7:TR?=	NHPlUXFUSU6JRWK=
NCI-H1694	NFHaWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGOxUVRKSzVyPUCuPVE5PzZizszN	MVPTRW5ITVJ?
CCF-STTG1	M2f2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnn2TWM2OD1yLkmyOlM4KM7:TR?=	MWXTRW5ITVJ?
K052	NYHIOnQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HhRWlEPTB;MD65OFA1PyEQvF2=	MYrTRW5ITVJ?
NCI-H446	NUPvZ5c5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\zcI9WUUN3ME2wMlk2ODFizszN	NYjDd3EyW0GQR1XS
MFE-280	M3j1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmX5TWM2OD1yLkm2NlkyKM7:TR?=	M2O0TXNCVkeHUh?=
KU812	Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG[0eolKSzVyPUCuPVk{QDlizszN	MoDwV2FPT0WU
MDA-MB-361	M1L4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwOUm3O\|ch\|ryP	NEXYV3FUSU6JRWK=
Raji	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XWPGlEPTB;MT6wNlI3PyEQvF2=	Mn3EV2FPT0WU
TE-6	NVLFdFJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlX5TWM2OD1zLkCzOVY3KM7:TR?=	MmHHV2FPT0WU
CAL-148	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnf0TWM2OD1zLkC0OFQ{KM7:TR?=	MoDuV2FPT0WU
NCI-H1963	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3i3dmlEPTB;MT6wOFU2OyEQvF2=	MX3TRW5ITVJ?
SK-N-AS	M4LDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIW0RZpKSzVyPUGuNFQ3QDVizszN	MYnTRW5ITVJ?
RERF-LC-MS	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTFwME[zOFkh\|ryP	NFzQ[IxUSU6JRWK=
BEN	MmnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXS2fnFEUUN3ME2xMlA4OTN5IN88US=>	NHWzRYdUSU6JRWK=
CAS-1	Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTFwMEmxNlMh\|ryP	NIjyWlNUSU6JRWK=
SW780	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTFwMEmxPFEh\|ryP	NUW2d\|JrW0GQR1XS
LU-65	NX7uRZZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHXTWM2OD1zLkC5OFEh\|ryP	M3[3dXNCVkeHUh?=
D-283MED	M4[1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTFwMUKyO\|Ih\|ryP	NHnNW3ZUSU6JRWK=
HCC2157	NHLMO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mor3TWM2OD1zLkGzOlQzKM7:TR?=	NXLlVFZbW0GQR1XS
RCC10RGB	NGnwfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTFwMUSwNFYh\|ryP	NV3HT2xTW0GQR1XS
PLC-PRF-5	NHnCNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzrfpdKSzVyPUGuNVUzOjlizszN	NXP6XHBxW0GQR1XS
H4	MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTFwMUW0N\|kh\|ryP	NUnUTY5kW0GQR1XS
TUR	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTFwMUW3OVIh\|ryP	MX3TRW5ITVJ?
NCI-H2141	Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHHTWM2OD1zLkG4PVQ3KM7:TR?=	MX\TRW5ITVJ?
PFSK-1	NWf5To9tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUf6VXRzUUN3ME2xMlIxPTN{IN88US=>	NUTseXNnW0GQR1XS
SK-MEL-28	NV36cYduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXGUItPUUN3ME2xMlI{OjJzIN88US=>	M{f2[3NCVkeHUh?=
SCC-9	MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\YfGlEPTB;MT6yN\|Y3PSEQvF2=	NHrQVYJUSU6JRWK=
T47D	NEj5SJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVT3cIZNUUN3ME2xMlI{Pjl4IN88US=>	M4TXN3NCVkeHUh?=
TCCSUP	M1nvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXZTWM2OD1zLkK1NFI6KM7:TR?=	NHH0V4RUSU6JRWK=
SU-DHL-1	NV;LZYtoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTFwMkWxNVgh\|ryP	NWLIRYI2W0GQR1XS
HL-60	NHLSVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLhTWM2OD1zLkK1OVg5KM7:TR?=	NW\iW5VNW0GQR1XS
NCI-H1436	M2nncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHGyeYhKSzVyPUGuNlYyPDlizszN	MkLYV2FPT0WU
DMS-114	NVjHOZRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\LT3ZKSzVyPUGuNlY3OzJizszN	MUPTRW5ITVJ?
BOKU	MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTFwMkiwPVUh\|ryP	M4LyRnNCVkeHUh?=
MS-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTFwMkmwOlkh\|ryP	NGHZemNUSU6JRWK=
NCI-H661	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;WdWlEPTB;MT6zNFQ4QCEQvF2=	M37sfXNCVkeHUh?=
HT-3	MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYm3RWNiUUN3ME2xMlMxPTJ7IN88US=>	NEPkfHJUSU6JRWK=
CAL-54	NVXPfJN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoS2TWM2OD1zLkOwO\|I2KM7:TR?=	NXHEPHRCW0GQR1XS
SW1463	NXPHb3NDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTFwM{G4O\|Ih\|ryP	MlLEV2FPT0WU
COLO-668	M{XKV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\lPGlEPTB;MT6zN\|A2PiEQvF2=	NGHmSXRUSU6JRWK=
PANC-08-13	M1\ofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjrZ5pmUUN3ME2xMlM{QDB\|IN88US=>	M3r0PHNCVkeHUh?=
BB49-HNC	MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDRcnpKSzVyPUGuN\|QxOSEQvF2=	MYDTRW5ITVJ?
M059J	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fTPWlEPTB;MT6zOVg{OiEQvF2=	MlznV2FPT0WU
NCCIT	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmntTWM2OD1zLkO3PVg5KM7:TR?=	NEPn[JdUSU6JRWK=
LN-405	MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjOWWN5UUN3ME2xMlM6OjZ2IN88US=>	MnvRV2FPT0WU
UMC-11	Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LIOGlEPTB;MT6zPVk6PiEQvF2=	MWPTRW5ITVJ?
NB5	MlTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTFwNEGyNlch\|ryP	NX7oZXNJW0GQR1XS
TE-441-T	NV;hTGpKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\ueGlEPTB;MT60NlgyPyEQvF2=	MlvhV2FPT0WU
ME-180	NXXFWZhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYe5e3h3UUN3ME2xMlQ1Ozl{IN88US=>	MU\TRW5ITVJ?
HCC70	M1npVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTFwNE[wPVYh\|ryP	NITte25USU6JRWK=
no-10	M4SyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\iNWVKSzVyPUGuOFYyQDFizszN	NHHmNlFUSU6JRWK=
JEG-3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTFwNUCxN\|Ih\|ryP	M3jEdnNCVkeHUh?=
no-11	MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfNT3dpUUN3ME2xMlUxQDh{IN88US=>	M37hbXNCVkeHUh?=
CHP-126	NEL2fZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rsW2lEPTB;MT61OlY6OSEQvF2=	NHvWS2NUSU6JRWK=
EGI-1	NF;sWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DUemlEPTB;MT61PFAzPSEQvF2=	MYnTRW5ITVJ?
D-392MG	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{f3[GlEPTB;MT61PVY{KM7:TR?=	MojuV2FPT0WU
RT4	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrreHZKSzVyPUGuOVk3OzdizszN	Mn3OV2FPT0WU
A204	Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvCbW9KSzVyPUGuOVk5ODFizszN	NUXNcFB{W0GQR1XS
NCI-H1304	NHXpU\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnucpJKSzVyPUGuOlM2QTFizszN	NIGwZVFUSU6JRWK=
Becker	MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzI[nRMUUN3ME2xMlY1OjRzIN88US=>	MUPTRW5ITVJ?
OE19	NFjUZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHe4O2lKSzVyPUGuOlU2OThizszN	NV\Fb\|B{W0GQR1XS
EKVX	NGjtflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTvW3dZUUN3ME2xMlY2PjF6IN88US=>	NXzZTZlrW0GQR1XS
KLE	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vmVWlEPTB;MT62OVcyPCEQvF2=	M3XjSHNCVkeHUh?=
K-562	Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;WeXZKSzVyPUGuOlcxOzdizszN	NG\BNXFUSU6JRWK=
MDA-MB-175-VII	NGjCVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;PTWM2OD1zLk[4PVk4KM7:TR?=	MmfTV2FPT0WU
NCI-H716	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4H3eGlEPTB;MT62PVMxPCEQvF2=	MmexV2FPT0WU
Caov-3	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTFwNkm0NVMh\|ryP	NXLuZVF5W0GQR1XS
HCC1187	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYD6OFA3UUN3ME2xMlcxPTR3IN88US=>	M4fMSHNCVkeHUh?=
CAKI-1	M{LGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3S2dGlEPTB;MT63NlI6OiEQvF2=	MV;TRW5ITVJ?
MOLT-16	Mo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTFwN{OzNFch\|ryP	NWPBdFVtW0GQR1XS
PC-3	NUC1XZZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEm3WmZKSzVyPUGuO\|UxQCEQvF2=	NF;kW5lUSU6JRWK=
DV-90	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;0fGlEPTB;MT63OVU5PSEQvF2=	NIDIR2ZUSU6JRWK=
RXF393	NEPrV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\R[Wd5UUN3ME2xMlc4Ojl2IN88US=>	NWLzc5Z2W0GQR1XS
SK-NEP-1	Mo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGO5bVRKSzVyPUGuPFI{OzlizszN	NWi2NVZQW0GQR1XS
HCC1419	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfUTWM2OD1zLkiyOlkzKM7:TR?=	MmPUV2FPT0WU
BV-173	NWjVeJlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LRe2lEPTB;MT64Nlk6PSEQvF2=	M4TMcHNCVkeHUh?=
MKN7	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XIZmlEPTB;MT64PVIzKM7:TR?=	M4n4VHNCVkeHUh?=
LAN-6	M37SRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mkm5TWM2OD1zLki5OVU{KM7:TR?=	M1r5dnNCVkeHUh?=
Mo-T	M2DvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvSSFE1UUN3ME2xMlkxODN7IN88US=>	NGTUNGNUSU6JRWK=
HCC1395	Moj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTFwOUK4OlMh\|ryP	M{\JV3NCVkeHUh?=
HC-1	M{flTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWryOZhFUUN3ME2xMlk{PDdizszN	M2\KZnNCVkeHUh?=
HPAF-II	MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTFwOUS0NVgh\|ryP	M{fLXXNCVkeHUh?=
CPC-N	NXj2U5RxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vkOGlEPTB;MT65PFAxOiEQvF2=	MYDTRW5ITVJ?
MKN45	NUn0TIRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWP2OXB3UUN3ME2xMlk6OTF7IN88US=>	NHrPbGFUSU6JRWK=
NCI-H1693	M1S0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTJwMEC0N\|Mh\|ryP	M{fOPXNCVkeHUh?=
SHP-77	M1rxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHCb25GUUN3ME2yMlAxPTN\|IN88US=>	MYDTRW5ITVJ?
NCI-H1522	NELGdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTJwMEG3NlQh\|ryP	MYHTRW5ITVJ?
SW1573	NHPuXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHjRWZnUUN3ME2yMlAzOiEQvF2=	Mm\iV2FPT0WU
DBTRG-05MG	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHZWGhCUUN3ME2yMlA3ODh5IN88US=>	MUDTRW5ITVJ?
SCC-4	MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXPXYpKSzVyPUKuNVQ{OSEQvF2=	NGTsTHZUSU6JRWK=
DMS-153	NV7SZ5I{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXnS4xKSzVyPUKuNVY3PjhizszN	NVfOVYpGW0GQR1XS
MDA-MB-415	NYT5[oU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3T5SmlEPTB;Mj6xO\|UzKM7:TR?=	M2G1R3NCVkeHUh?=
NCI-H2126	MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTJwMkK4PFgh\|ryP	MV7TRW5ITVJ?
MDA-MB-453	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTJwMkOzNkDPxE1?	M{HFNnNCVkeHUh?=
U-87-MG	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTJwMki1PVIh\|ryP	MnfaV2FPT0WU
LNCaP-Clone-FGC	M{nudGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHGTWM2OD1{LkOwNVAzKM7:TR?=	MnuzV2FPT0WU
NCI-H1581	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHz5coRKSzVyPUKuN\|IyODVizszN	MUfTRW5ITVJ?
BC-3	NEnKZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTJwM{[1NFkh\|ryP	NWHsXo9RW0GQR1XS
HCC38	NHrGZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1j5dmlEPTB;Mj6zPFQ1PyEQvF2=	NWLFRos3W0GQR1XS
HCC2218	MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTJwNEC4NFkh\|ryP	MYLTRW5ITVJ?
RO82-W-1	NXv1R2dYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTJwNEGyOUDPxE1?	NUm5SnltW0GQR1XS
C2BBe1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDxTWM2OD1{LkSxOVc5KM7:TR?=	Mnu4V2FPT0WU
LAMA-84	MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmTITWM2OD1{LkW3N\|Y5KM7:TR?=	M13RSnNCVkeHUh?=
GMS-10	NV3mN21nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoOyTWM2OD1{LkW3OlEyKM7:TR?=	MlvSV2FPT0WU
GCT	Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYroeVhNUUN3ME2yMlU5Pjl2IN88US=>	M1jWR3NCVkeHUh?=
SK-CO-1	NUHBOXJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTJwNkG2OkDPxE1?	MUDTRW5ITVJ?
NCI-H526	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPRTWM2OD1{Lk[zOFUh\|ryP	NFu3b3pUSU6JRWK=
SW1088	NInURYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTJwN{e4N\|kh\|ryP	NYDSN25DW0GQR1XS
HT55	MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLtTWM2OD1{Lke4Olk2KM7:TR?=	MlOxV2FPT0WU
NB10	M3zScmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPPW\|Z{UUN3ME2yMlgyPzR6IN88US=>	MlTzV2FPT0WU
UACC-893	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4Pv[2lEPTB;Mj64OVc1QSEQvF2=	M2K4T3NCVkeHUh?=
NCI-H1618	NVXjXnpRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHNTWM2OD1{Lki4NVU{KM7:TR?=	M4jabHNCVkeHUh?=
NCI-H1092	NX:5VHFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTNwMEe4NVIh\|ryP	NUK3XG95W0GQR1XS
SBC-1	M{XVbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTNwMEi1OVMh\|ryP	M3fyU3NCVkeHUh?=
NCI-H1623	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHzT3NKSzVyPUOuNFk{PCEQvF2=	M{DURXNCVkeHUh?=
SiHa	Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF:4fG5KSzVyPUOuNVE6PzdizszN	NF;zNpFUSU6JRWK=
D-263MG	M2TYN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTNwMUS3PFgh\|ryP	M{\CfXNCVkeHUh?=
NCI-H1573	NFr4eWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPBTWM2OD1\|LkG5OlQyKM7:TR?=	M2TpUXNCVkeHUh?=
NCI-H82	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\UelRKSzVyPUOuN\|Q1OzlizszN	M3jLd3NCVkeHUh?=
NCI-H2196	NXzKc5Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\jWW14UUN3ME2zMlM2ODB6IN88US=>	NUnpSllmW0GQR1XS
MFM-223	NXu1TFFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mof2TWM2OD1\|LkO3N\|UyKM7:TR?=	NF\3TI9USU6JRWK=
COLO-678	MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTNwM{ixPFYh\|ryP	MV\TRW5ITVJ?
EW-3	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrER45KSzVyPUOuOFA6PSEQvF2=	NX7ZVXV1W0GQR1XS
MHH-NB-11	M1n4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTFTWM2OD1\|LkS0NFY6KM7:TR?=	MXXTRW5ITVJ?
EM-2	MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTNwNkO5PEDPxE1?	M4jDfXNCVkeHUh?=
FTC-133	M3Ozb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDBTWM2OD1\|Lk[1OFU5KM7:TR?=	MVvTRW5ITVJ?
NCI-H209	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPBTWM2OD1\|Lk[3OlU{KM7:TR?=	M3fjdXNCVkeHUh?=
TGBC24TKB	M3e2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDCRZVKSzVyPUOuOlg{PTVizszN	MnnJV2FPT0WU
LC-1F	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn:yTWM2OD1\|LkexO\|Y1KM7:TR?=	NH7YcWpUSU6JRWK=
C-4-II	NGnkc25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3ZNVRMUUN3ME2zMlc2PjR\|IN88US=>	NH7LXJNUSU6JRWK=
NCI-H1650	M2Dkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PzWmlEPTB;Mz63PFQ2PSEQvF2=	NVu2VnFvW0GQR1XS
JVM-2	NWTkTGN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnMZ3dKSzVyPUOuPVM3OzlizszN	NYnlR4dYW0GQR1XS
CaR-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnz4TWM2OD1\|Lkm3OlE4KM7:TR?=	M2fpZnNCVkeHUh?=
MDA-MB-134-VI	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTRwMEK5OVIh\|ryP	MY\TRW5ITVJ?
NCI-H719	MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPFXnJJUUN3ME20MlE2Ozh6IN88US=>	MV3TRW5ITVJ?
GOTO	M1i2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7XS25KSzVyPUSuNlk4ODVizszN	MlThV2FPT0WU
NCI-N87	MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIqxfHBKSzVyPUSuN\|g5OjFizszN	NF20XmxUSU6JRWK=
NB6	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjadJhKSzVyPUSuOFI2ODlizszN	MnHTV2FPT0WU
DSH1	NGHmbFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33NeGlEPTB;ND60O\|EyPiEQvF2=	NV7aV5JCW0GQR1XS
BT-20	M4roRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvXRXJKSzVyPUSuOFkxODJizszN	MofHV2FPT0WU
NCI-H1882	M1L4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nEd2lEPTB;ND61NFU4KM7:TR?=	NH[5UHVUSU6JRWK=
WM-115	NUPQSWZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\ufoo1UUN3ME20MlUxQDhzIN88US=>	MlW1V2FPT0WU
SKG-IIIa	MmrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzOTWM2OD12Lk[3O\|ch\|ryP	MnP3V2FPT0WU
NCI-H69	NEnmTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\BeGlEPTB;ND63NFI4PSEQvF2=	M4jSXXNCVkeHUh?=
MSTO-211H	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnG3TWM2OD12LkizOVY2KM7:TR?=	NXHGXFFTW0GQR1XS
Mewo	NWnycXVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XSXmlEPTB;ND65OlMyOyEQvF2=	NFP0SZhUSU6JRWK=
GI-ME-N	NXTUdJRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInrbGtKSzVyPUWuNFA2ODlizszN	MXjTRW5ITVJ?
T98G	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXUXJYzUUN3ME21MlA3PTB6IN88US=>	NH:5WGRUSU6JRWK=
ECC4	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXOxRplnUUN3ME21MlA6Ozd{IN88US=>	M4DMU3NCVkeHUh?=
EW-11	M1vEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIf5[XVKSzVyPUWuNVgxQTlizszN	MXrTRW5ITVJ?
COLO-800	MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXuxN45{UUN3ME21MlE6OzR7IN88US=>	NIPn[o5USU6JRWK=
NCI-H1755	MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3zfIZXUUN3ME21MlI{ODJ5IN88US=>	NGi3eHdUSU6JRWK=
KMS-12-PE	MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;LfJNKSzVyPUWuN\|UxQDVizszN	MmfqV2FPT0WU
HCC1954	NVHJ[GJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmToTWM2OD13Lki1PVcyKM7:TR?=	Mk\SV2FPT0WU
NCI-H187	NYPuZnduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTVwOUK5PFkh\|ryP	NILoW3JUSU6JRWK=
LU-165	NGS1N3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jRO2lEPTB;NT65PVAxOiEQvF2=	NF\ybZZUSU6JRWK=
YAPC	MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfZcnZFUUN3ME21Mlk6ODZ6IN88US=>	Mn\6V2FPT0WU
LU-139	NYfHb2dYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vBNWlEPTB;Nj6wPFM3QCEQvF2=	NHrDOWVUSU6JRWK=
D-502MG	M376OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13PTmlEPTB;Nj6zNlA1PyEQvF2=	MVTTRW5ITVJ?
IST-SL1	MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIP6clRKSzVyPU[uOVM6PDhizszN	MWPTRW5ITVJ?
DG-75	M13zdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvuTIZKSzVyPU[uPFg4QDZizszN	MoLMV2FPT0WU
NCI-H1155	MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TmfWlEPTB;Nj65OVU5OSEQvF2=	NHflOnZUSU6JRWK=
EFE-184	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTdwM{G2PVUh\|ryP	NX;J[IZQW0GQR1XS
AsPC-1	NXrVeGh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;zfGRKSzVyPUeuOFg5ODdizszN	M2fhZ3NCVkeHUh?=
SW948	M{nH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTdwNUizPVUh\|ryP	MXnTRW5ITVJ?
NCI-H524	NVWyU\|F4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHmdG1KSzVyPUmuOVg3OjhizszN	M3G3XHNCVkeHUh?=
KOSC-2	M1i5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDOTWM2OD17Lk[yPFM1KM7:TR?=	NYHpUoZZW0GQR1XS
T-24	M3[0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonCTWM2OD17Lkm0OFE2KM7:TR?=	NEHTXZVUSU6JRWK=
NCI-H748	MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTFyLk[zPVch\|ryP	M3rzZnNCVkeHUh?=
NCI-H23	Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1v4SGlEPTB;MUCuOlQ1OiEQvF2=	MkfPV2FPT0WU
UACC-812	NEjYZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnFTWM2OD1zMT63NVch\|ryP	NIjQdHdUSU6JRWK=
SCLC-21H	MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjRTpZtUUN3ME2xNk4yPTVzIN88US=>	NUO1UoN1W0GQR1XS
NCI-SNU-16	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfQTnVbUUN3ME2xN{4yOjV6IN88US=>	NXO5R4cyW0GQR1XS
HD-MY-Z	NVfjbllvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPVTWM2OD1zND62N\|Y{KM7:TR?=	NHzIeoxUSU6JRWK=
SK-N-FI	Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;wO2d3UUN3ME2xOE45QTF{IN88US=>	MorQV2FPT0WU
LB647-SCLC	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLaO4RmUUN3ME2xOU44OTl3IN88US=>	MWLTRW5ITVJ?
NCI-H345	M3L0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGqyOXRKSzVyPUG3MlM1OyEQvF2=	NVzBS3BXW0GQR1XS
NCI-H1563	M1;Zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTF6Lke2NFEh\|ryP	MUDTRW5ITVJ?
RL	NYHSeYRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrnTWM2OD1{MT6yOlU3KM7:TR?=	MVPTRW5ITVJ?
KY821	Ml;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTJ{LkC1OVMh\|ryP	NVSyV2JZW0GQR1XS
JVM-3	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTJ3LkC0NVMh\|ryP	NUjwVI5uW0GQR1XS
NCI-H1793	MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIW1Z4xKSzVyPUK4MlU1QTlizszN	MlGzV2FPT0WU
LU-134-A	NH20T2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3:yNmlEPTB;M{CuNlA{PyEQvF2=	M4HqWnNCVkeHUh?=
NCI-H1395	NYX3eldTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2j4RWlEPTB;M{KuNlQ{OSEQvF2=	NWfXZVhpW0GQR1XS
NCI-H1993	NWjBdXUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fCbmlEPTB;M{KuPFIyQCEQvF2=	NFvEV2tUSU6JRWK=
P31-FUJ	NGnPO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETaNmlKSzVyPUOzMlQ5QTlizszN	M4LqPXNCVkeHUh?=
LS-513	NUHXSGg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLhNohxUUN3ME2zOU45QDd7IN88US=>	MlXzV2FPT0WU
SK-MEL-1	M13Kemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fkb2lEPTB;NECuN\|Q6QSEQvF2=	M{P6T3NCVkeHUh?=
SW684	NGrXbHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnZVXNGUUN3ME20N{46PjZzIN88US=>	MXrTRW5ITVJ?
COR-L88	NF;ZWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;NPI5KSzVyPUS0MlA3PjVizszN	MoP6V2FPT0WU
NCI-H889	NIm1OmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTR3LkCwPFch\|ryP	NFrXbmtUSU6JRWK=
TALL-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTR4LkGxPVkh\|ryP	NEPIflFUSU6JRWK=
KARPAS-299	M1LhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPFXIdjUUN3ME20O{4yQTl\|IN88US=>	M2WyXHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo

Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. ^[1]

Protocol

Kinase Assay:^[1]	+ Expand Bcl-2 Binding affinity calculation: A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. ^[4] As a control in determining the reliability of the calculation, predicted binding affinities K_i) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.
Cell Research:^[2]	+ Expand Cell lines: Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) Concentrations: ~10 μM Incubation Time: 48-72 hours Method: Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 10⁴ per well for HMCLs or 5~10 × 10³ for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used. Formulation: Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 m Dosages: 0.0313, 0.25, 0.5 and 2 mg/kg Administration: Administered intravenously (tail vein) once a day (Only for Reference)

References

[4] Naim M, et al. J Chem Inf Model, 2007, 47(1), 122-133.

+ Expand

Solubility (25°C)

In vitro	DMSO	83 mg/mL (200.73 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Molecular Weight	413.49
Formula	C₂₀H₁₉N₃O.CH₄O₃S
CAS No.	803712-79-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01563601	Withdrawn	Extensive-stage Small Cell Lung Cancer	Cephalon\|Teva Pharmaceutical Industries	August 2012	Phase 3
NCT01238146	Withdrawn	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Splenic Marginal Zone Lymphoma	National Cancer Institute (NCI)	October 2010	Phase 1\|Phase 2
NCT01150656	Completed	Leukemia	Children''s Oncology Group\|National Cancer Institute (NCI)	June 2010	--
NCT00933985	Terminated	Acute Leukemias of Ambiguous Lineage\|Acute Undifferentiated Leukemia\|Angioimmunoblastic T-cell Lymphoma\|Blastic Phase Chronic Myelogenous Leukemia\|Childhood Burkitt Lymphoma\|Childhood Chronic Myelogenous Leukemia\|Childhood Diffuse Large Cell Lymphoma\|Childhood Immunoblastic Large Cell Lymphoma\|Childhood Nasal Type Extranodal NK/T-cell Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Hepatosplenic T-cell Lymphoma\|Intraocular Lymphoma\|Noncutaneous Extranodal Lymphoma\|Peripheral T-cell Lymphoma\|Recurrent Childhood Acute Lymphoblastic Leukemia\|Recurrent Childhood Acute Myeloid Leukemia\|Recurrent Childhood Anaplastic Large Cell Lymphoma\|Recurrent Childhood Grade III Lymphomatoid Granulomatosis\|Recurrent Childhood Large Cell Lymphoma\|Recurrent Childhood Lymphoblastic Lymphoma\|Recurrent Childhood Small Noncleaved Cell Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent/Refractory Childhood Hodgkin Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Relapsing Chronic Myelogenous Leukemia\|Small Intestine Lymphoma\|Unspecified Childhood Solid Tumor Protocol Specific	National Cancer Institute (NCI)	June 2009	Phase 1
NCT00521144	Completed	Recurrent Small Cell Lung Cancer\|Unspecified Adult Solid Tumor Protocol Specific	National Cancer Institute (NCI)	August 2007	Phase 1\|Phase 2
NCT00427856	Completed	Lymphoma Follicular	Gemin X\|Teva Pharmaceutical Industries	March 2007	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Pan Bcl-2 Inhibitor

ABT-737 : Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.
Most Potent Bcl-2 Inhibitor

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products4

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Navitoclax (ABT-263)

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Venetoclax (ABT-199, GDC-0199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Obatoclax Mesylate (GX15-070)

Cited by 26 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Obatoclax Mesylate (GX15-070)

Cited by 26 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)